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Abstract 
Context: Although open radical cystectomy (ORC) is still the standard approach, laparoscopic 
radical cystectomy (LRC) and robot-assisted radical cystectomy (RARC) are increasingly 
performed.  
Objective: To report on a systematic literature review and cumulative analysis of pathologic, 
oncologic, and functional outcomes of RARC in comparison with ORC and LRC. 
Evidence acquisition: Medline, Scopus, and Web of Science databases were searched using a 
free-text protocol including the terms robot-assisted radical cystectomy or da Vinci radical 
cystectomy or robot* radical cystectomy. RARC case series and studies comparing RARC with 
either ORC or LRC were collected. A cumulative analysis was conducted. 
Evidence synthesis: The searches retrieved 105 papers, 87 of which reported on pathologic, 
oncologic, or functional outcomes. Most series were retrospective and had small case numbers, 
short follow-up, and potential patient selection bias. The lymph node yield during lymph node 
dissection was 19 (range: 3±55), with half of the series following an extended template (yield 
range: 11±55). The lymph node±positive rate was 22%. The performance of lymphadenectomy 
was correlated with surgeon and institutional volume. Cumulative analyses showed no 
significant difference in lymph node yield between RARC and ORC. Positive surgical margin 
(PSM) rates were 5.6% (1±1.5% in pT2 disease and 0±31% in pT3 and higher disease). PSM 
rates did not appear to decrease with sequential case numbers. Cumulative analyses showed no 
significant difference in rates of surgical margins between RARC and ORC or RARC and LRC. 
Neoadjuvant chemotherapy use ranged from 0% to 31%, with adjuvant chemotherapy used in 4±
22% of patients. Only six series reported a mean follow-up of >36 mo. Three-year disease-free 
survival (DFS), cancer-specific survival (CSS), and overall survival (OS) rates were 53±74%, 
68±83%, and 72±80%, respectively. The 5-yr DFS, CSS, and OS rates were 53±74%, 66±80%, 
and 39±66%, respectively. Similar to ORC, disease of higher pathologic stage or evidence of 
lymph node involvement was associated with worse survival. Very limited data were available 
with respect to functional outcomes. The 12-mo continence rates with continent diversion were 
83±100% in men for daytime continence and 66±76% for nighttime continence. In one series, 
potency was recovered in 63% of patients who were evaluable at 12 mo. 
Conclusions: Oncologic and functional data from RARC remain immature, and longer-term 
prospective studies are needed. Cumulative analyses demonstrated that lymph node yields and 
PSM rates were similar between RARC and ORC. Conclusive long-term survival outcomes for 
RARC were limited, although oncologic outcomes up to 5 yr were similar to those reported for 
ORC.  
Patient summary: Although open radical cystectomy (RC) is still regarded as the standard 
treatment for muscle-invasive bladder cancer, laparoscopic and robot-assisted RCs are becoming 
more popular. Templates of lymph node dissection, lymph node yields, and positive surgical 
margin rates are acceptable with robot-assisted RC. Although definitive comparisons with open 
RC with respect to oncologic or functional outcomes are lacking, early results appear 
comparable. 
1. Introduction 
Radical cystectomy and pelvic lymph node dissection (PLND) is the gold standard treatment for 
muscle-invasive bladder cancer (MIBC) and high-risk non±muscle-invasive disease [1]. Patients 
undergoing this operation can experience 66% recurrence-free survival at 10 yr after surgery [2]. 
The addition of neoadjuvant platinum-based chemotherapy has been shown to improve overall 
survival (OS) rates by approximately 5% [3]. Robot-assisted radical cystectomy (RARC) was 
initially described by Menon et al in 2003 [4]. Over time, many international centers have 
adopted RARC.  
Oncologic outcomes from large population-based cohorts of RARC with lengthy follow-up are 
lacking. Early on in RARC history, surrogates for oncologic control were reported using positive 
surgical margin (PSM) rates and lymph node yields. More recently, 5-yr survival figures have 
become available. The majority of these outcomes, however, capture institutions early in their 
learning curves and incorporate patients potentially selected for the robotic technique, thus 
avoiding more advanced-stage or technically difficult cases. Data on functional consequences of 
RARC are even more limited; therefore, the quality of nerve sparing and its effect on potency 
recovery and continence are inadequately understood. 
 Because of the expanding evidence available in the field of RARC, and in preparation for the 
Pasadena international consensus meeting on best practice in RARC and urinary reconstruction, 
we performed a systematic literature review of perioperative, functional, and oncologic outcomes 
of RARC in comparison with open radical cystectomy (ORC) and laparoscopic radical 
cystectomy (LRC). 
We report on the systematic review and cumulative analysis of oncologic and functional 
outcomes of RARC. We systematically examined lymph node yields, PSMs, cancer-specific 
survival (CSS), recurrence-free survival, and OS. In addition, functional outcomes after RARC, 
including urinary continence and erectile function, were systematically examined. 
2. Evidence acquisition 
A systematic literature search was initially performed in September 2013 using the Medline, 
Scopus, and Web of Science databases. The searches included only a free-text protocol using the 
terms robot-assisted radical cystectomy or da Vinci radical cystectomy or robot* radical 
cystectomy in all the fields of the records for Medline and Scopus searches and in the Title and 
Topic fields for the Web of Science search. No limits were applied. A full update of the searches 
was performed on April 28, 2014.  
Two authors (G.N. and B.Y.) separately reviewed the records to select RARC case series and 
studies that compared RARC with ORC and RARC with LRC. Discrepancies were resolved by 
open discussion. Other significant studies cited in the reference lists of the selected papers were 
evaluated, as were studies published after the systematic search.  
All noncomparative studies reporting the following data on RARC were collected: intraoperative 
and perioperative data (operative time, blood loss, transfusion rate, in-hospital stay, readmission, 
complication rates), functional data (urinary continence, erectile function), and oncologic data 
(PSMs, lymph node yield, disease-free survival [DFS], CSS, OS). The present review included 
only studies reporting on functional and oncologic data.  
Studies reporting on partial cystectomy, prostate-sparing cystectomy, salvage cystectomy, 
cystectomy for urachal cancer or benign disease, single-case reports, pure laparoscopic (or 
mixed) series, or laparoendoscopic single-site or natural orifice transluminal endoscopic surgery 
for radical cystectomy; experimental studies on animal models; congress abstracts; review 
papers; editorials; population-based studies; and book chapters were not included in the review. 
All data retrieved from the selected studies were recorded in an electronic database.  
All papers were categorized according to the 2011 levels of evidence (LOEs) for therapy studies: 
LOE 1, systematic review of randomized trials or n-of-1 trials; LOE 2, randomized trial or 
observational study with dramatic effect; LOE 3, nonrandomized controlled cohort/follow-up 
study; LOE 4, case series, case±control study, or historically controlled study; or LOE 5, 
mechanism-based reasoning [5]. Papers were categorized according to the IDEAL 
recommendations [6].  
2.1. Statistical analysis 
Cumulative analysis was conducted using Review Manager v5.2 software designed for 
composing Cochrane Reviews (Cochrane Collaboration, Oxford, UK). Statistical heterogeneity 
was tested using the chi-square test. A p value <0.10 was used to indicate heterogeneity. Where 
there was a lack of heterogeneity, fixed-effects models were used for the cumulative analysis. 
Random-effects models were used in case of heterogeneity. For continuous outcomes, the results 
were expressed as weighted mean differences and standard deviations (SDs); for dichotomous 
variables, results were given as odds ratios (ORs) and 95% confidence intervals (CIs). Because 
of limitations in the Review Manager v5.2 software, meta-analysis of continuous variables was 
possible only when rough data were presented as mean and SD. Authors of the papers were 
contacted to provide missing data, whenever necessary. For all statistical analyses, two-sided p < 
0.05 was considered statistically significant.  
3. Evidence synthesis 
3.1. Quality of the studies and level of evidence 
Figure 1 shows a flowchart of this systematic review of the literature.  
In total, 65 surgical series [4,7±70] and 22 comparative studies [71±92] reported on pathologic, 
oncologic (n = 18), or functional (n = 9) outcomes of RARC.  
Most surgical series were retrospective, single-center studies (LOE 4). Exceptions included 
prospective studies [8,22,28,35,36,43,52,59,64,66,81,87] and some multi-institutional 
retrospective collaboration studies [16,23,25,30,45,48,54,61,68]. Only two of the comparative 
studies were randomized [74,83] (LOE 2b); all other comparative studies were nonrandomized, 
whether prospective or retrospective (LOE 4). 
3.2. Pathologic information 
3.2.1. Lymph node yields with robot-assisted radical cystectomy 
Table 1 summarizes the number of lymph nodes recovered in published RARC series. The 
majority of studies (86%) reported extent of lymph node dissection (LND), with more centers 
performing extended LND (ELND) in recent series. Standard LND typically involved the 
removal of obturator, internal iliac, external iliac, and some portion of the common iliac lymph 
nodes bilaterally. ELND templates typically brought the proximal extent up to the aortic 
bifurcation or inferior mesenteric artery. Approximately half of the analyzed studies reported 
following an extended template of dissection.  
The lymph node yield from all series was 19 (range: 3±55). Initial descriptions using a standard 
template of dissection achieved yields of 18 lymph nodes [59]. Number of lymph nodes 
recovered with an ELND ranged from 11 to 55. Abaza et al adopted a robotic template similar to 
the open technique, including external iliac, obturator, hypogastric, common iliac, and presacral 
up to the aortic bifurcation; the mean lymph node yield was 37.5 (SD: 13.2), demonstrating that 
lymph node counts could mirror those of open dissection if the same template was followed [88]. 
In a study of open completion LND after robot-assisted ELND in 11 men, Davis et al removed 
only an additional 4 lymph nodes with an open approach after 43 were removed with robot 
assistance [34]. Time of LND was rarely reported, although it ranged from 44 min in standard 
LND to 117 min in ELND [8,34]. The lymph node±positive rate was 22%. In series with >20 
RARCs, lymph node±positive rates ranged from 6% to 42%. Reports of vascular injuries were 
rare, and lymphocele rates were 0±9%. 
3.2.2. Patient characteristics and surgical aspects influencing lymph node yields with robot-
assisted radical cystectomy 
Table 2 summarizes the studies assessing the effects of patient characteristics and particular 
surgical aspects on lymph node yields in RARC series. Cumulative analysis from the 
International Robotic Cystectomy Consortium (IRCC) with respect to lymphadenectomy in 437 
patients found a median of 17 lymph nodes removed, with a 20% node-positivity rate [23]. 
Patient age and sex did not affect the performance of lymphadenectomy. In a different series, 
increasing body mass index (BMI) did not appear to negatively affect lymph node yield, with 
>20 lymph nodes removed in normal, overweight, and obese patients [46]. 
It is interesting to note that in single-institution series, Richards et al [38], Schumacher et al [39], 
Guru et al [59], and Pruthi et al [60] did not find higher lymph node yields with increasing 
sequential case numbers. However, in the IRCC, performance of lymphadenectomy was 
positively correlated with surgeon and institution volume but was reduced in patients with more 
advanced disease (pT4 stage), which may reflect operative avoidance of bulky nodal tissue.  
3.2.3. Positive surgical margin rates with robot-assisted radical cystectomy 
Table 3 summarizes the occurrence of PSMs reported in the RARC series. The reported PSM 
rates were 5.6% (range: 0±26%). However, in series of >100 patients, margin rates ranged 
between 4% and 9% [48,53]. PSMs were reported in 1±1.5% of patients with pT2 disease and 0±
31% of patients with pT3 and higher disease. PSM rates from the IRCC in 939 cases were 9% 
[53].  
3.2.4. Patient characteristics and surgical aspects influencing positive surgical margin rates 
with robot-assisted radical cystectomy 
Table 4 summarizes the studies assessing the effects of patient characteristics and particular 
surgical aspects on PSM rates in RARC series. Notably, Richards et al [38], Schumacher et al 
[39], and the IRCC [68] did not demonstrate decreasing surgical margin rates with sequential 
case number. In a study of the role of previous robot-assisted radical prostatectomy (RARP) 
experience on RARC outcomes, there was a trend toward increased positive margins with 
increasing RARP volumes, but it did not reach statistical significance (p = 0.089) [61]. The 
authors chiefly attributed this situation to the performance of RARC on patients with higher risk 
(higher than T3) disease. One study reported that PSMs occurred only in the overweight or obese 
patients, although pT4 rates were much higher in those patients (26% vs 7%) [65]. 
3.3. Oncologic information 
3.3.1. Chemotherapy use in robot-assisted radical cystectomy 
Table 5 summarizes the oncologic outcomes of current RARC publications. Neoadjuvant 
chemotherapy use was reported in 0±31% of patients. Adjuvant chemotherapy use was reported 
in 4±22% of patients. 
Several studies further analyzed the use of adjuvant chemotherapy after RARC. General 
indications for selecting patients for adjuvant chemotherapy included pathologic stage pT3±4 or 
node-positive disease. Pruthi et al described the use of adjuvant chemotherapy in 18 of 100 
RARC patients, with mean time to chemotherapy initiation at approximately 7 wk, which was 
faster than the authors¶ historical time to chemotherapy in open cystectomy of 10 wk [31]. In a 
randomized trial of RARC (n = 21) compared with ORC (n = 20), 7 wk was also the mean time 
to initiation of chemotherapy after RARC [74]. In one analysis of patients with node-positive 
disease at the time of RARC, 46% received adjuvant chemotherapy [45]. 
3.3.2. Survival outcomes after robot-assisted radical cystectomy 
Survival represents the gold standard with respect to evaluating effectiveness and risks of 
treatment; however, RARC reports with 5-yr outcomes have become available only recently. 
Data remain limited for assessing long-term outcomes, patterns of recurrence, and means for 
predicting survival. The role of adjuvant treatments after RARC is also poorly defined.  
Series detailing cancer control outcomes had a mean follow-up between 6 and 84 mo (Table 5), 
although only 6 of 18 series (33%) reported a mean follow-up >36 mo. At 1, 2, 3, and 5 yr, DFS 
was 82±96%, 67±81%, 67±76%, and 53±74%, respectively; CSS was 88±94%, 75±89%, 68±
83%, and 66±80%, respectively; and OS was 82±90%, 54±89%, 72±80%, and 39±66%, 
respectively. In the series with longest follow-up, Khan et al described only 14 patients with 5 
yr of follow-up, showing DFS of 50%, CSS of 75%, and OS of 64% [66].  
Several series reported on adverse oncologic outcomes associated with increased pathologic 
stage or lymph node involvement [58,93]. In a series of 162 patients with urothelial carcinoma, 
Yuh et al found that 5-yr survival was worse with higher pathologic stage or lymph node 
positivity (p < 0.01). Patients with a lymph node density of 1±10% (defined as number of 
positive nodes divided by number of total nodes) had DFS, CSS, and OS of 34%, 49%, and 31%, 
respectively, whereas patients with lymph node density >10% had further reduced survival of 
30%, 38%, and 20%, respectively. Predictors of DFS were lymph node density, pathologic stage, 
and age-adjusted Charlson comorbidity index, whereas the same measures plus receipt of 
transfusion were predictive for OS [58]. Similarly, in an analysis of 99 patients with follow-up 
>5 yr, pathologic stage and lymph node positivity were independent predictors of DFS, CSS, and 
OS, whereas positive margin status and Charlson comorbidity index predicted worse OS and 
CSS [70]. 
In series with median follow-up of >36 mo, rates of local recurrence without distant disease 
ranged between 0% (n = 15) and 9% (n = 99) [57,58,66,67,70]. No port-site recurrences occurred 
in these series. Xylinas et al examined 175 patients with a median follow-up of 37 mo, showing 
recurrence of disease in 29%. Of these patients, 8 (5%) had local recurrence alone, 11 had local 
and distant metastases, and 32 had distant metastases alone [57]. 
In an analysis of patients with positive lymph nodes (n = 50) at the time of PLND, median time 
to recurrence was 10 mo after RARC [45]. Estimated OS at 36 and 60 mo was 55% and 45%, 
respectively, with recurrence-free survival at 36 and 60 mo of 43% and 39%, respectively. 
Similarly, Tyritzis et al reported recurrence-free survival of 34% and OS of 63% after 24 mo in 
node-positive patients [56]. 
3.4. Functional information 
3.4.1. Continence after urinary diversion and robot-assisted radical cystectomy 
Table 6 presents the RARC series reporting on continence outcomes. Although functional 
outcomes are a major area of study in patients undergoing RARP, a lack of data remains for 
evaluation after RARC. Worldwide, the number of patients evaluated for continence after 
orthotopic bladder substitution is <200 from nine reports at the present time. There are also 
widespread differences in patient selection, methods of data collection, and outcome assessment.  
Follow-up for continence evaluation varied widely, from 6 to 25 mo. Nerve-sparing procedures 
were performed in 20±100% of patients. Only three of six series reported using a distinct 
definition for continence, which was generally no pad or one pad (safety) per day. One of the 
earliest RARC series reported an 86% continent rate (seven of eight men) after 3.5 mo [9]. More 
recent series published 6-mo continence rates of 48±100% for daytime continence and 11±100% 
for nighttime continence. At 12 mo after RARC, continence rates ranged from 83% to 100% in 
men and were 67% in women for daytime continence and 66±76% for nighttime continence. 
Using strict definitions for daytime continence (no or one security pad per day) and nighttime 
continence (good indicates dry with no protection, fair indicates dry with one awakening), Canda 
et al examined 23 patients with intracorporeal Studer pouch. After excluding patients who died 
or were lost to follow-up, 11 of 15 men (73%) and 0 of 2 women were continent during the 
daytime. Three of these 17 patients (18%) had good nighttime continence, and 4 (24%) had fair 
continence [33]. 
Only one series has described continence results in patients undergoing RARC and continent 
cutaneous diversion. Torrey et al examined 34 patients who had RARC and Indiana pouch 
continent cutaneous diversion and reported 97% continence at a mean follow-up of 20 mo for 
both daytime and nighttime. One patient continued to experience daytime and nighttime 
incontinence requiring the use of pads [41]. 
3.4.2. Potency recovery after robot-assisted radical cystectomy 
Table 7 summarizes the series examining potency outcomes. Similar to continence outcomes, 
evaluation of erectile function after RARC is not well described. Early reports suggest that 
erections sufficient for penetration are achievable, although sample sizes were very small and 
lacked validated objective evaluations. Follow-up was again too short to form definitive 
conclusions, with only one study reporting outcomes up to 2 yr after RARC. As noted earlier, 
nerve-sparing procedures were performed in 20±100% of patients. The data recording used 
International Index of Erectile Function (IIEF) scores in five of seven series. However, only 
three series provided a clear definition of potency [12,35,56].  
In some early, small series, Mottrie et al [9] and Murphy et al [12] reported sufficient erections 
in six of seven and three of four men, respectively. Similar to well-described literature on RARP, 
phosphodiesterase type 5 inhibitors (PDE5-Is) were frequently administered to patients for penile 
rehabilitation after RARC; however, no comparative data in this setting have demonstrated a 
benefit. 
Several series with intracorporeal neobladder have evaluated erectile function postoperatively, 
with varying results. In the experience of the Karolinska Institute, 41 of 62 men (66%) 
underwent nerve-sparing RARC. Of these 41 men, 26 (63%) were potent with or without the use 
of PDE5-Is after 12 mo [56]. In contrast, Canda et al found IIEF scores >18 in only 1 of 11 
preoperatively potent men, although follow-up was shorter (6 mo) [33]. 
3.5. Cumulative analysis of studies comparing robot-assisted radical cystectomy with open or 
laparoscopic radical cystectomy 
Table 8 summarizes comparative studies evaluating lymph node yield after ORC, LRC, and 
RARC. In two randomized studies of ORC compared with RARC, lymph node yields were not 
statistically different [74,83]. Cumulative analyses showed no significant difference in lymph 
node yield between RARC and ORC (OR: 2.94; 95% CI, í.28 to 6.15; p = 0.07) (Fig. 2). 
Table 9 summarizes PSM rates in RARC, ORC, and LRC. In two randomized trials comparing 
RARC and ORC, Nix et al and Parekh et al did not show any increase in positive margins with 
RARC [74,83]. Cumulative analyses showed no significant difference in rates of surgical 
margins between RARC and ORC (5% and 7%, respectively; OR: 0.71; 95% CI, 0.46±1.1; p = 
0.13) (Fig. 3). In two comparative nonrandomized studies between RARC and LRC, no 
significant differences in PSM rates were detected (p = 0.86) [87,89]. 
Table 10 summarizes series that emphasized early oncologic comparisons for RARC, LRC, and 
ORC, though interpretation should be cautious with small series of shorter follow-up and 
potential bias of patient selection. A nonrandomized comparison of ORC (n = 52) with RARC (n 
= 48) with a follow-up of 38 mo showed disease-specific survival of 69% in the ORC group 
compared with 79% in the RARC group [87]. A series by Nepple et al showed similar estimates 
in DFS, CSS, and OS, although patients were not matched [82]. 
3.6. Discussion 
Our systematic review sought to identify and report the current state of the literature for RARC 
with regard to pathologic, oncologic, and functional outcomes. Various oncologic parameters, 
including pathologic findings and postoperative survival rates, were examined. With regard to 
nodal dissection, robotic ELND achieves a similar nodal yield to open ELND when performed 
by experienced surgeons. Nearly all RARC series reported nodal yields >15. With regard to 
margin rates, most series reported PSM rates of <10%, with rates of approximately 1% in pT2 
disease. Although the IRCC (n = 513) reported a very high positive margin rate of 39% in pT4 
patients, other authors have reported rates similar to those noted in ORC series.  
Although these immediate pathologic variables may act as surrogates for quality of resection, 
long-term survival outcomes must be analogous to those of ORC for RARC to be a viable 
surgical option. Currently, oncologic data are immature, and adequate comparative studies of 
RARC and ORC are nonexistent. In a few analyses measuring CSS and OS at 5 yr 
postoperatively, results appear similar to those reported in ORC; however, larger numbers and 
longer follow-up are needed for adequate comparison. At present, data reporting functional 
analysis of continence and potency recovery after RARC are inadequate to compare RARC 
reliably with ORC. 
PLND, in conjunction with radical cystectomy, provides a staging benefit as well as a possible 
advantage for survival in retrospective studies. Stein et al examined 1054 patients treated with 
radical cystectomy and PLND with a 24% node-positive rate; these patients experienced 5- and 
10-yr recurrence-free survival of 35% and 34%, respectively [2]. Although prospective 
validation is necessary, Leissner et al suggested that ELND improved outcomes in both low-
volume node-positive and node-negative patients with greater number of lymph nodes removed 
[93]. The true survival benefit of ELND must be proven in a prospective fashion to overcome the 
Will Rogers phenomenon of apparent improved survival that results from stage migration with 
more thorough dissection.  
Early critical concerns of RARC involved whether LND could be performed robotically with the 
same quality as during ORC. This review suggests that thorough robotic ELND dissection at the 
time of RARC is possible following a similar template as is performed during ORC. Half of 
current RARC series describe an extended template dissection, with the average number of 
lymph nodes removed between 11 and 55. In a small study of open completion LND after 
robotic LND, only four additional lymph nodes were recovered [34]. Although few series 
described the time necessary to perform a complete robotic LND, some authors described 
operative times approaching 2 h for the node dissection alone, suggesting that robotic LND may 
lengthen operative time. Further study is necessary to determine whether the LND segment of 
RARC is significantly longer compared with open LND. Complications specific to LND²
particularly vascular injuries²were rare, as were lymphoceles, with an incidence <10%. 
However, complication rates may often be underreported, as reporting guidelines lack 
standardization. 
Assessment of RARC lymph node yields as related to patient characteristics (eg, BMI) or 
surgeon characteristics (eg, prior RARP experience) has not shown a specific association. 
Similar to the ORC literature, Bochner et al reported that only extent of LND was associated 
with lymph node yield when examining variables such as receipt of neoadjuvant chemotherapy, 
pathologic stage, surgeon, and pathologist [94]. Although performance of LND was associated 
with higher surgeon volume, analysis of several learning curve evaluations did not find increases 
in lymph node yield with increasing case number. This result may seem counterintuitive, but it 
may be that these experienced robotic surgeons were able to translate surgical technique from 
RARP and PLND and thus reduce the number of cases needed to reach stable lymph node yields. 
Instead, a reduction in LND time could occur with experience, although it has not been 
specifically examined. In the IRCC database, patients with pT4 disease had lower nodal yields, 
possibly related to more difficult dissection or to RARC being performed for palliative intent.  
PSM at cystectomy is a measure of disease burden and a predictor of outcome. In a previous 
study of 1589 patients who underwent radical cystectomy at Memorial Sloan Kettering Cancer 
Center, the positive margin rate was 4.2%. Risk factors for PSMs were female sex, higher 
pathologic stage, vascular invasion, mixed histology, and lymph node involvement. Patients with 
PSMs had a 5-yr CSS of only 32% [95]. In another large multi-institutional analysis of 4400 
ORC patients, the incidence of PSMs was 6.3% [96]. A potential challenge of RARC and 
limitation of current robotic technology is in treating bulkier tumors because of the lack of tactile 
feedback.  
The present systematic review demonstrates that PSMs are uncommon in RARC series and 
appropriately rare for pT2 disease. No significant difference was found when comparing the 
surgical margin rate between RARC and ORC. The high variability of positive margins across 
studies, between 0% and 26%, suggests significant heterogeneity in cancer characteristics, 
patient selection, and surgical technique and experience, among other variables. From the 
systematic review, the weighted average of positive margins in RARC series was 5.6%, which is 
comparable to the large open series cited earlier. In the aforementioned analysis of 4400 ORC 
patients, margin-positive rates by stage were 2.3% for pT2, 7.6% for pT3, and 24% for pT4 
disease [96]. The effects of the learning curve as institutions adopted this new technology and 
patient selection toward earlier stage disease likely affected reported margin rates and should be 
considered when interpreting outcomes. Nonetheless, higher reported rates of positive margins in 
pT4 disease in some RARC series suggest that caution be taken for higher stage disease, with 
particular attention paid to the risk of margin involvement. 
Several RARC series did not show decreasing margin rates with sequential case volume. A few 
reasons could explain this observation: (1) The positive margin numbers may be too low to 
detect a subgroup difference; (2) the learning curve for reducing margins at RARC could be 
extremely high, with a number not yet reached in smaller learning curve assessments; or (3) over 
time, more experienced surgeons may be more willing to take on bulky or higher stage tumors. 
This final hypothesis is supported by a multivariate analysis adjusting for pathologic stage that 
shows that differences in stage of disease accounted for an increase in margin rates with more 
experienced robotic surgeons [61]. 
Chemotherapy use alongside surgery in the treatment of MIBC can be implemented either before 
or after cystectomy. While neoadjuvant chemotherapy has been shown to confer an OS 
advantage of 5% in randomized trials [97], the benefit of adjuvant chemotherapy is less proven. 
In a recent meta-analysis of nine randomized controlled trials comprising 945 patients that 
investigated the use of adjuvant chemotherapy, benefits to both OS and DFS were appreciated. 
Patients receiving adjuvant chemotherapy after cystectomy had 23% relative risk reduction in the 
risk of death (OS: p = 0.049) and 34% relative decrease in the risk of disease recurrence (DFS: p 
= 0.014) [98]. For the current systematic review, neoadjuvant chemotherapy use was 0±31%, and 
adjuvant chemotherapy was delivered to 4±22% of patients. Adjuvant therapy was chiefly 
administered in patients with advanced-stage pT3 or higher or with positive lymph nodes. 
Although time to initiation of adjuvant chemotherapy was shorter by 3 wk in the analysis by 
Pruthi et al, further validation is required [31]. 
Long-term freedom from disease recurrence and bladder cancer±related death is the primary 
measure of treatment efficacy with radical cystectomy. Particularly with assessments of survival, 
gathering data for comparison with the open standard is challenging secondary to the necessity of 
controlling for cancer characteristics, additional therapies, and the length of follow-up required 
to detect significant differences. Shorter-interval examinations of survival may not amply capture 
events such as local recurrence, distant recurrence, or secondary therapies. Only two series in 
this systematic review compared survival for RARC and ORC. These studies were not 
randomized and included sequential series of retrospective groups (LOE 4) [82,87]. In a series by 
Nepple et al, 36 patients who underwent RARC were compared with 29 patients who underwent 
ORC with a median follow-up of only 12 mo. Estimated 2-yr DFS (67% vs 58%), CSS (75% vs 
63%), and OS (68% vs 63%) after RARC and ORC were similar for the two techniques, 
respectively [82].  
Because of limitations of present studies, comparisons must be made to large historical 
retrospective open series. A long-term analysis of survival in 1100 chemotherapy-naive 
cystectomy patients by Hautmann et al demonstrated 10-yr CSS and OS rates of 67% and 44%, 
respectively [99]. For this systematic review, 5-yr estimates for DFS, CSS, and OS were 63±
74%, 66±80%, and 39±66%, respectively. Analogous to stratified outcomes in ORC, survival 
outcomes were worse in RARC series with increasing pathologic stage and with lymph node 
metastases. Local control of disease appears to be adequate such that the majority of recurrences 
after RARC are distant or outside the pelvis. A potential concern for port-site metastases with 
RARC remains of particular interest. Although no specific published series address this concern 
and most larger RARC oncologic series did not report any incidents, a few case reports suggest 
that this concern requires further study. 
Since the original description of neurovascular bundle preservation during radical prostatectomy 
by Walsh et al, techniques to improve functional outcomes through meticulous nerve sparing 
have been translated to radical cystectomy. Turner et al determined that nerve sparing improved 
urinary continence after orthotopic urinary diversion [100], and nerve sparing has been shown to 
assist with recovery of erectile function objectively based on IIEF [101]. Long-term functional 
evaluations of ileal neobladder continent diversions have demonstrated daytime continence rates 
of 92% and nighttime continence rates of 80% [102].  
To date, very limited data are available regarding functional outcomes of continence or potency 
after RARC. These analyses have chiefly been limited to only a few centers that exhibit 
significant heterogeneity. The 12-mo reported continence rates were 88±100% in men and 67% 
in women for daytime continence and between 66% and 75% for nighttime continence. Potency 
recovery exhibited even greater variation, with sufficient erection rates between 9% and 81%. 
Functional outcomes are likely influenced by patient factors and selection, comorbidity, prior 
treatments, surgeon experience, and technique (eg, the use of cautery vs clips). In addition, 
methodology of reporting, definitions of continence, measurement tools, rehabilitation programs, 
and inconsistencies in follow-up can affect the actual measurement of continence and potency. 
Specific functional concerns of RARC related to patient selection are that many patients may be 
older or have poor baseline erectile function. Moreover, technical concerns for a possible PSM, 
which portends a dismal outcome, may affect the performance of nerve sparing. The lack of 
conclusive data regarding functional recovery after RARC is a necessary area for future study.  
There is no evidence to date that the results from a recent systematic review on RARP finding 
slight advantages to continence and potency recovery compared with open radical prostatectomy 
or laparoscopic radical prostatectomy extrapolate to RARC [103]. Precise definitions of 
continence and potency are necessary so that future data acquisition can be carried out in a 
standardized, stringent, and uniform fashion for both ORC and RARC. 
From a methodological perspective, the most relevant limitations of this systematic review are 
the quality of the available studies, the small number of patients in and the retrospective nature 
of most series, the shorter-term follow-up of these studies, and the lack of standardized 
definitions. The papers included in the present review included only two small randomized 
controlled trials; the remaining series are LOE 3 or 4. Comparisons made in these single-
institution studies inevitably carry the risk of selection bias. Even in randomized controlled 
studies, there were unlikely to have been equally experienced open and robotic surgeons 
operating on comparable patients. Heterogeneity in lymph node templates, sampling methods, 
specimen handling, and pathologic review may affect lymph node yields. Most cumulative 
outcomes were weighted by the results of experienced surgeons, which may make conclusions 
difficult to generalize. The inability to account for surgeon factors or specific technique 
modifications is another limitation. Most series failed to provide specific information concerning 
relevant aspects of the reconstructive portions of the operation. 
4. Conclusions 
Sufficient lymph node yields are achievable through robotic PLND if an extended template is 
followed. PSM rates appear similar with RARC and ORC. Conclusive long-term survival 
outcomes for RARC are limited, although oncologic outcomes of 5 yr are similar to those 
reported for ORC. Initial functional outcomes appear favorable; however, additional research on 
continence and potency after RARC is needed. 
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Figure legends 
 
Fig. 1 ± Flowchart of the systematic review. 
 
Fig. 2 ± Comparison of lymph node yields following robot-assisted or open radical 
cystectomy.  
CI = confidence interval; ORC = open radical cystectomy; RARC = robot-assisted radical 
cystectomy; SD = standard deviation. 
 
Fig. 3 ± Comparison of positive surgical margin rates following robot-assisted or open 
radical cystectomy.  
CI = confidence interval; M-H = Mantel-Haenszel; ORC = open radical cystectomy; RARC 
= robot-assisted radical cystectomy. 
 
 
Table 1 ± Lymph node yields in robot-assisted radical cystectomy series 
 
Reference Institution IDEAL 
stage 
Cases, 
no. 
Study 
design 
Extension 
of LND 
Operative 
time, min 
Retrieved 
nodes, no. 
pN+, 
%  
Metastatic 
nodes, 
median, no. 
Complications 
due to LND 
Menon et al, 2003 [4]  Henry Ford Hospital 1 17 Retrospective Standard Ȃ Ȃ 6 Ȃ Ȃ 
Menon et al, 2004 [7] Henry Ford Hospital 1 3 female Retrospective Standard Ȃ 12 0 Ȃ Ȃ 
Guru et al, 2007 [8] Roswell Park Cancer Institute 1 20 Prospective Standard 44 13 15 1 Ȃ 
Mottrie et al, 2007 [9] O.L.V.ȂClinic 2a 27 Retrospective Extended Ȃ 23 9 Ȃ  Ȃ 
Pruthi et al, 2008 [71] UNC 2a 20 Retrospective Standard Ȃ 19 10 Ȃ Ȃ 
Hemal et al, 2008 [10] All India Institute of Medical 
Sciences 
1 6 Retrospective Standard Ȃ 12 17 Ȃ Ȃ 
 
Lowentritt et al, 2008 
[11] 
Tulane University 2a 4 Retrospective Standard Ȃ 12 25 Ȃ Ȃ 
Murphy et al, 2008 
[12] 

ǯ Hospital 2a 23 Retrospective Standard Ȃ 16 9 Ȃ Ȃ 
Park et al, 2008 [13] Yonsei 2a 4 Retrospective Standard Ȃ 17 0 Ȃ Ȃ 
Pruthi et al, 2008 [14] UNC 2a 12 female Retrospective Standard, 
then 
extended 
Ȃ 19 17 Ȃ Ȃ 
Pruthi et al, 2008 [15] UNC 2b 50 Retrospective Standard  Ȃ 19 20 Ȃ Ȃ 
Wang et al, 2008 [72] Cornell 2b 33 Retrospective Standard Ȃ 17 19 Ȃ Ȃ 
Woods et al, 2008 
[16] 
Mayo Arizona 2b 27 Multi-
institutional 
Extended Ȃ 12.3 33 3.1 0 
Tulane University 
Yuh et al, 2008 [17] Roswell Park Cancer Institute 2a 54 Retrospective Extended Ȃ 17 Ȃ Ȃ Ȃ 
Gamboa et al , 2009 
[18] 
University of California, 2a 41 Retrospective Standard Ȃ 23 14 4 Ȃ 
 Irvine 
Pruthi et al, 2009 [19] UNC 2b 50 Retrospective Standard, 
then 
extended 
Ȃ 19 16 Ȃ Ȃ 
10 female 19 
40 male 18 
Table
Palou Redorta et al, 
2009 [20] 
Barcelona Autonomous 
University 
2a 9 Retrospective Extended 60 10 0 Ȃ Ȃ 
Yuh et al, 2009 [21] Roswell Park Cancer Institute 2b 73 Retrospective Extended Ȃ 19 Ȃ Ȃ Ȃ 
Guru et al, 2010 [22] Roswell Park Cancer Institute 2a 26 Prospective Extended Ȃ 21 29 1 Internal iliac 
artery 
injury: 1 
Hellenthal et al, 2011 
[23] 
IRCC 2b 437 Multi-
institutional 
Ȃ Ȃ 17 20 Ȃ Ȃ 
Josephson et al, 2010 
[24] 
City of Hope Cancer Center 2b 58 Retrospective Extended Ȃ 27 24 Ȃ Ȃ 
Kang et al, 2010 [25] Multicenter 2b 71 
standard 
LND 
Retrospective Standard Ȃ 15.7 10 Ȃ Ȃ 
33 
extended 
LND 
Extended 24.7 
Kasraeian et al, 2010 
[26] 
Montsouris Institute 2a 9 Retrospective Extended Ȃ 11 22 Ȃ 0 
Kauffman et al, 2011 
[27] 
Cornell 2b 85 Retrospective Extended Ȃ 19 15 Ȃ Ȃ 
Kwon et al, 2010 [28] Kyungpook National University 2a 17 Prospective Standard Ȃ 6 6 1 0 
Lavery et al, 2011 [29] Ohio State University 2a 15 Retrospective Extended 107 41.8 20 Ȃ 0 
Martin et al, 2010 [30] Mayo Arizona 2b 59 Multi-
institutional 
Extended Ȃ Ȃ 34 Ȃ Ȃ 
Tulane University 
Ng et al, 2010 [73] Cornell 2b 83 Retrospective Standard Ȃ 16 16 Ȃ Ȃ 
Nix et al, 2010 [74] UNC 3 21 RCT Standard Ȃ 19 19 Ȃ Ȃ 
Pruthi et al, 2010 [31] UNC 2b 100 Retrospective Standard, 
then 
extended 
Ȃ 19 20 Ȃ Ȃ 
Richards et al, 2010 
[75] 
Wake Forest University 2b 35 Retrospective Extended Ȃ 16 29 Ȃ Ȃ 
Akbulut et al, 2011 
[32] 
Ankara Ataturk Training and 
Research Hospital 
2a 12 Not reported Extended Ȃ 21.3 42 Ȃ 8 
Canda et al, 2012 [33] Ankara Ataturk Training and 
Research Hospital 
2a 27 Not reported Extended Ȃ 24.8 22 Ȃ Ȃ 
Davis et al, 2011 [34] University of Texas M.D. 
Anderson Cancer Center 
2a 11 Retrospective Extended 117 43 9 1 Ȃ 
Jonsson et al, 2011 
[35] 
Karolinska Institute 2b 45 Prospective Standard Ȃ 19 20 Ȃ Ȃ 
36 Extended 19 17 
neobladd
er 
  
9 ileal 
conduit 
27 33 
Khan et al, 2011 [36] 
ǯ 2a 50 Prospective Ȃ Ȃ 17 Ȃ Ȃ Ȃ 
Manoharan et al, 2011 
[37] 
University of Miami 2a 14 Retrospective Standard Ȃ 12 Ȃ Ȃ Ȃ 
Martin et al, 2011 [76] Mayo Arizona 2b 19 Retrospective Ȃ Ȃ 16 Ȃ Ȃ Ȃ 
Richards et al, 2011 
[38] 
Wake Forest University 2b 60 Retrospective Extended Ȃ 17 30 Ȃ Lymphocele: 1 
Schumacher et al, 
2011 [39] 
Karolinska Institute 2b 45 Retrospective Standard 
49%, 
extended 
31% 
Ȃ 22.5 Ȃ 1.5 Lymphocele: 2 
Shah et al, 2011 [40] Ohio State University 2b 30 Retrospective Extended Ȃ Ȃ 30 Ȃ Ȃ 
Torrey et al, 2011 [41] City of Hope Cancer Center 2b 34 Retrospective Extended Ȃ 28.9 Ȃ Ȃ Ȃ 
Cho et al, 2012 [42] Hallym University College of 
Medicine 
2b 35 Retrospective Standard Ȃ Ȃ 6 Ȃ Ȃ 
Goh et al, 2012 [43] Keck School of Medicine, 
University of Southern 
California, Los Angeles 
2a 15 Prospective Superextende
d 
Ȃ 55 26 Ȃ Ȃ 
Lau et al, 2012 [44] City of Hope Cancer Center 2b 23 (aged 
>80 yr) 
Retrospective Extended Ȃ 20.4 22 Ȃ Ȃ 
Mmeje et al, 2013 [45] Mayo Arizona 2b 50 Multi-
institutional 
Extended Ȃ 18 100 3 Ȃ 
UNC 
Poch et al, 2012 [46] Roswell Park Cancer Institute 2b 56 Retrospective Ȃ Ȃ 25 16 Ȃ Ȃ 
Richards et al, 2012 
[77] 
Wake Forest University 2b 20 (aged 
>75 yr) 
Retrospective Extended Ȃ 17 35 Ȃ Ȃ 
Saar et al, 2013 [47] Saarland University 2b 62 Retrospective Ȃ Ȃ 14.2 21 Ȃ Ȃ 
Smith et al, 2012 [48] Mayo Arizona 2b 227 Multi-
institutional 
Ȃ Ȃ 18 20 Ȃ Ȃ 
UNC, Tulane University 
Styn et al, 2012 [78] University of Michigan 2b 50 Retrospective Ȃ Ȃ 14.3 12 Ȃ Ȃ 
Sung et al, 2012 [79] Samsung Medical Center 2b 35 Retrospective Standard Ȃ 19.1 26 Ȃ Lymphocele: 1 
Treiyer et al, 2012 
[49] 
Saarland University 2b 91 Retrospective Standard Ȃ 14.5 14 Ȃ Ȃ 
Tsui et al, 2012 [50] Chang Gung Memorial Taiwan 2a 8 Retrospective Standard Ȃ 3 12.50 Ȃ Ȃ 
Yuh et al, 2012 [51] City of Hope Cancer Center 2b 196 Retrospective Extended Ȃ 28 22 Ȃ Lymphocele: 3 
Collins et al, 2013 [52] Karolinska Institute 2b 113 Prospective Extended 
56%, 
standard 
34%, limited 
5%, none 5% 
Ȃ 21 20 Ȃ Lymphocele: 5 
Johar et al, 2013 [53] IRCC 2b 939 Multi-
institutional 
Ȃ Ȃ 18.1 26 Ȃ Ȃ 
Maes et al, 2013 [80] Metro Health Hospital 2b 14 Retrospective Extended Ȃ 11.9 7 Ȃ Ȃ 
Marshall et al, 2013 
[54] 
IRCC 2b 765 Multi-
institutional 
Extended 
58%, 
standard 
40%, no LND 
2% 
Ȃ 18 27 Ȃ Ȃ 
Musch et al, 2014 [81] Klinikin EssenȂMitte 2b 100 Prospective Ȃ Ȃ 26.5 20 Ȃ Lymphocele: 4 
Nazmy et al, 2014 
[55] 
City of Hope Cancer Center 2b 209 Retrospective Extended Ȃ Ȃ 22 Ȃ Lymphocele: 3 
Nepple et al, 2013 
[82] 
Washington University 2b 36 Retrospective Standard Ȃ 17 22 Ȃ Ȃ 
Parekh et al, 2013 
[83] 
University of Texas Health 
Sciences Center at San Antonio 
3 20 RCT Standard Ȃ 11 20 Ȃ Ȃ 
Tyritzis et al, 2013 
[56] 
Karolinska Institute 2b 70 Retrospective Standard 
43% 
Ȃ 21 14 Ȃ Lymphocele: 6 
Extended 
48% 
  
Lymphedema: 1 
  
Xylinas et al, 2013 
[57] 
Cornell 2b 175 Retrospective Standard  Ȃ 19 17 Ȃ Lymphocele: 2 
Phillips et al, 2014 
[69] 
Seward St. Elizabeth Medical 
Center 
2b 23 (>80 
yr) 
Retrospective Extended Ȃ 19 Ȃ Ȃ   
Raza et al, in press 
[70] 
Roswell Park Cancer Institute 2b 99 Retrospective Ȃ Ȃ 20.7 36 Ȃ Ȃ 
Yuh et al, 2014 [58] City of Hope Cancer Center 2b 162 Retrospective Extended Ȃ 28 23 Ȃ Ȃ 
Total       19.3 23   
 
IRCC = International Robotic Cystectomy Consortium; LND = lymph node dissection; RCT = randomized controlled trial; UNC = 
University of North Carolina. 
 
Table 2 ± Impact of patient characteristics and surgical aspects on lymph node yield in robot-assisted radical cystectomy series 
 
Reference Institution 
IDEAL 
Cases 
Study 
design 
Extension 
of LND 
Operative 
time, min 
Retrieved 
nodes, no. 
pN+, % 
stage 
Patient BMI                 
Poch et al, 
2012 [46] 
Roswell Park Cancer 
Institute 
2b 
56 
Retrospective Ȃ Ȃ 
25 16 
BMI <25: 14 22 7 
BMI 25 to <30: 21 23 14  ? ? ?ǣ ? ? 20 24 
Case volume                 
Guru et al, 
2008 [59] 
Roswell Park Cancer 
Institute 
2a 
1Ȃ12 
Prospective Extended 
46 33% >13 8 
13Ȃ24 44 66% >13 33 
25Ȃ36 41 83% >13 25 
37Ȃ47 43 72% >13 64 
48Ȃ58 56 91% >13 18 
Pruthi et al, 
2008 [60] 
University of North 
Carolina 
2b 
50 
Retrospective Standard Ȃ 
19 
Ȃ 1Ȃ10 21 11Ȃ20 19 
21Ȃ30 20 
31Ȃ40 17 
41Ȃ50 20 
Richards et al, 
2011 [38] 
Wake Forest University 2b 
60 
Retrospective Extended Ȃ 
17 
30 
1Ȃ20 17 
21Ȃ40 19.1 
41Ȃ60 14.4 
Schumacher 
et al, 2011 
[39] 
Karolinska Institute 2b 
45 
Retrospective 
Standard 49% 
Ȃ 22.5 Ȃ Extended 31% 1Ȃ15 Standard 40% 
Extended 7% 
16Ȃ30 Standard 47% 
Extended 53% 
Table
31Ȃ45 Standard 60% 
Extended 33% 
Prior RARP 
experience 
                
Hayn et al, 
2010 [61] 
IRCC 2b 
496 
Retrospective Ȃ Ȃ 
17.8 
Ȃ 
 ? ? ?ǣ 
83 
13.7 
51Ȃ100 previous 
RARP: 187 
19.8 
101Ȃ150 previous 
RARP: 176 
19.6 
>150 previous RARP: 
50 
11.8* 
BMI = body mass index; RCC = International Robotic Cystectomy Consortium; LND = lymph node dissection; RARP = robot-
assisted radical prostatectomy. 
*
 Statistically significant. 
Table 3 ± Positive surgical margins in robot-assisted radical cystectomy series 
 
 
Reference Institution 
IDEAL 
stage 
Cases, 
no. 
Study design 
Pathologic stage, % Overall 
PSM rate, 
% 
PSM location  
PSM rate, %  ? ?  ? ?  ? ?  ? ? 
Menon et al, 2003 
[4]  
Henry Ford 
Hospital 
1 17 Retrospective Ȃ Ȃ 0 Ȃ 0 0 
Yohannes et al, 
2003 [62] 
Creighton 
University 
1 2 Retrospective 0 100 0 Ȃ 0 0 
Menon et al, 2004 
[7] 
Henry Ford 
Hospital 
1 3 female Retrospective 66 33 0 Ȃ 0 0 
Rhee et al, 2006 
[84] 
University of 
Virginia 
1 7 Retrospective 43 57 0 Ȃ 0 0 
Guru, et al, 2007 
[8] 
Roswell Park 
Cancer 
Institute 
1 20 Prospective 40 60 15 
Prostate: 1 
Ureter: 1  
Vagina: 1 
0 25 
Mottrie et al, 2007 
[9] 
O.L.V.ȂClinic 2a 27 Retrospective 78 22 4 Ureter: 1 Ȃ Ȃ 
Pruthi et al, 2008 
[71] 
UNC 2a 20 Retrospective 70 20 0 
Ȃ 
0 0 
  
Hemal et al, 2008 
[10] 
All India 
Institute of 
Medical 
Sciences 
1 6 Retrospective 67 33 0 
Ȃ 
0 0 
 
  
Lowentritt et al, 
2008 [11] 
Tulane 
University 
2a 4 Retrospective 25 75 0 Ȃ 0 0 
Murphy et al, 2008 
[12] 

ǯ 
Hospital 
2a 23 Retrospective 74 17 0 Ȃ 0 0 
Park et al, 2008 
[13] 
Yonsei 2a 4 Retrospective 50 50 0 Ȃ 0 0 
Pruthi et al, 2008 
[14] 
UNC 2a 
12 
female 
Retrospective 58 25 0 Ȃ 0 0 
Pruthi et al, 2008 
[15] 
UNC 2b 50 Retrospective 66 14 0 Ȃ 0 0 
Pruthi et al, 2009 
[19] 
UNC 2b 
50 
Retrospective 
66 18 
0 
Ȃ 
0 0 
10 
female 
50 30   
40 male 70 15   
Wang et al, 2008 
[72] 
Cornell 2b 33 Retrospective 72 28 6 Perivesical fat: 2 0 22 
Woods et al, 2008 Mayo Arizona 2b 27 Multi-institutional Ȃ Ȃ 7 Ȃ 0 Ȃ 
Table
[16] Tulane 
University 
  
Yuh et al, 2008 
[17] 
Roswell Park 
Cancer 
Institute 
2a 54 Retrospective 44 56 13 Ȃ 0 23 
Gamboa et al, 
2009 [18] 
University of 
California, 
Irvine 
2a 41 Retrospective Ȃ Ȃ 5 Ȃ 0 Ȃ 
  
Palou Redorta et 
al, 2009 [20] 
Barcelona 
Autonomous 
University 
2a 9 Retrospective 66 33 11 
Ȃ Ȃ Ȃ 
  
Yuh et al, 2009 
[21] 
Roswell Park 
Cancer 
Institute 
2b 73 Retrospective 45 55 10 Ȃ 0 18 
Guru et al, 2010 
[22] 
Roswell Park 
Cancer 
Institute 
2a 20 Prospective 62 38 4 Ȃ 0 9 
Hayn et al, 2010 
[61] 
IRCC 2b 482 Multi-institutional 64 36 7 
Ȃ Ȃ Ȃ 
  
Hellenthal et al, 
2010 [68] 
IRCC 2b 513 Multi-institutional 64 36 7 Ȃ 1.50 17 
Kang et al, 2010 
[25] 
Multicenter 2b 104 Multi-institutional 70 30 5 Ȃ Ȃ Ȃ 
Kasraeian et al, 
2010 [26] 
Montsouris 
Institute 
2a 9 Retrospective 44 66 0 Ȃ Ȃ Ȃ 
Kauffman et al, 
2011 [27] 
Cornell 2b 85 Retrospective 64 36 6 Ȃ 0 16 
Kwon et al, 2010 
[28] 
Kyungpook 
National 
University  
2a 17 Prospective 59 41 0 Ȃ 0 0 
Martin et al, 2010 
[30] 
Mayo Arizona 
2b 59 Multi-institutional 47 53 Ȃ Ȃ Ȃ Ȃ Tulane 
University 
  
Ng et al, 2010 [73] Cornell 2b 83 Retrospective 61 39 7 Ȃ 0 19 
Nix et al, 2010 
[74] 
UNC 3 21 RCT 67 14 0 Ȃ 0 0 
Pruthi et al, 2010 
[31] 
UNC 2b 100 Retrospective 67 13 0 Ȃ 0 0 
Richards et al, 
2010 [75] 
Wake Forest 
University 
2b 35 Retrospective 60 40 3 Ȃ Ȃ Ȃ 
Akbulut et al, 2011 
[32] 
Ankara 
Ataturk 
Training and 
Research 
Hospital 
2a 12 Not reported 58 42 0 Ȃ 0 0 
Canda et al, 2012 
[33] 
Ankara 
Ataturk 
Rraining and 
Research 
Hospital 
2a 27 Not reported 56 44 4 Ȃ 0 4 
Davis et al, 2011 
[34] 
University of 
Texas M.D. 
Anderson 
Cancer 
Center 
2a 11 Retrospective 92 8 0 Ȃ Ȃ Ȃ 
Jonsson et al, 2011 
[35] 
Karolinska 
Institute 
2b 45 Prospective 78 22 2 Ȃ 0 10 
Khan et al, 2011 
[36] 

ǯ
Hospital 
2a 50 Prospective 72 28 2 Ȃ 0 7 
Manoharan et al, 
2011 [37] 
University of 
Miami 
2a 14 Retrospective Ȃ Ȃ 0 Ȃ 0 0 
Martin et al, 2011 
[76] 
Mayo Arizona 2b 19 Retrospective 42 58 Ȃ Ȃ Ȃ Ȃ 
  
Richards et al, 
2011 [38] 
Wake Forest 
University 
2b 60 Retrospective 63 37 10 Ȃ Ȃ Ȃ 
Schumacher et al, 
2011 [39] 
Karolinska 
Institute 
2b 45 Retrospective 78 22 2 Ureter: 1 0 10 
Shah et al, 2011 
[40] 
Ohio State 
University 
2b 30 Retrospective 65 35 7 Ȃ 0 22 
Cho et al, 2012 
[42] 
Hallym 
University 
College of 
Medicine 
2b 35 Retrospective 86 14 3 Ȃ Ȃ Ȃ 
Goh et al, 2012 
[43] 
Keck School 
of Medicine, 
University of 
Southern 
California, 
Los Angeles 
2a 15 Prospective 67 33 0 
Ȃ Ȃ Ȃ 
  
Lau et al, 2012 
[44] 
City of Hope 
Cancer 
Center 
2b 
23 (aged 
>80 yr) 
Retrospective 61 39 13 
Ureter: 1 Ȃ Ȃ 
  
Mmeje et al, 2013 
[45] 
Mayo Arizona 
2b 50 Multi-institutional 34 66 2 
Ȃ Ȃ Ȃ 
UNC   
Poch et al, 2012 
[46] 
Roswell Park 
Cancer 
Institute 
2b 56 Retrospective 55 45 Ȃ Ȃ Ȃ Ȃ 
Richards et al, 
2012 [77] 
Wake Forest 
University 
2b 
20 
Retrospective 60 40 5 
Ȃ Ȃ Ȃ  (aged 
>75 yr) 
  
Saar et al, 2013 
[47] 
Saarland 
University 
2b 62 Retrospective 64 36 2 Ȃ Ȃ Ȃ 
Smith et al, 2012 
[48] 
Mayo Arizona 
2b 227 Multi-institutional Ȃ Ȃ 2 Ȃ Ȃ Ȃ UNC, Tulane 
University 
  
Styn et al, 2012 
[78] 
University of 
Michigan 
2b 50 Retrospective 60 40 2 Ȃ Ȃ Ȃ 
Sung et al, 2012 
[79] 
Samsung 
Medical 
Center 
2b 35 Retrospective 43 57 Ȃ Ȃ Ȃ Ȃ 
Treiyer et al, 2012 
[49] 
Saarland 
University 
2b 91 Retrospective 67 33 2 
Urethra: 1 
Prostate: 1 
Ȃ Ȃ 
Tsui et al, 2012 
[50] 
Chang Gung 
Memorial  
2a 8 Retrospective 75 25 0 Ȃ 0 0 
Yuh et al, 2012 
[51] 
City of Hope 
Cancer 
Center 
2b 196 Retrospective 64 36 4 Ȃ Ȃ Ȃ 
Azzouni et al, 
2013 [63] 
Roswell Park 
Cancer 
Institute 
2b 100 Retrospective 35 65 4 Ȃ Ȃ Ȃ 
Collins et al, 2013 
[52] 
Karolinska 
Institute 
2b 113 Prospective 75 25 5 Ureter: 1 1 18 
Johar et al, 2013 
[53] 
Multicenter 2b 939 Retrospective 49 51 9 Ȃ Ȃ Ȃ 
Maes et al, 2013 
[80] 
Metro Health 
Hospital 
2b 14 Retrospective 43 57 21 Ȃ Ȃ Ȃ 
Marshall et al, 
2013 [54] 
IRCC 2b 765 Multi-institutional 59 41 Ȃ Ȃ Ȃ Ȃ 
Musch et al, 2014 
[81] 
Klinikin 
EssenȂMitte 2b 100 Prospective 61 39 2 Ȃ Ȃ Ȃ 
Nazmy et al, 2014 
[55] 
City of Hope 
Cancer 
Center 
2b 209 Retrospective 65 35 3 Ȃ Ȃ Ȃ 
Nepple et al, 2013 
[82] 
Washington 
University 
2b 36 Retrospective 53 47 6 Ȃ 0 12 
Parekh et al, 2013 
[83] 
University of 
Texas Health 
Sciences 
Center at San 
Antonio 
3 20 RCT 50 50 5 Ȃ 0 10 
Tyritzis et al, 2013 
[56] 
Karolinska 
Institute 
2b 70 Retrospective 86 14 1.5 Ureter: 1 0 10 
Xylinas et al, 2013 
[57] 
Cornell 2b 175 Retrospective 65 35 5 Ȃ Ȃ Ȃ 
Phillips et al, 2014 
[69] 
Seward St. 
Elizabeth 
Medical 
2b 
23 (aged 
>80 yr) 
Retrospective 30 70 26 Ȃ Ȃ Ȃ 
Center 
Raza et al, in press 
[70] 
Roswell Park 
Cancer 
Institute 
2b 99 Retrospective 48 52 8 Ȃ Ȃ   
Yuh et al, 2014 
[58] 
City of Hope 
Cancer 
Center 
2b 162 Retrospective 67 33 4 Ȃ Ȃ Ȃ 
Total     60 40 5.6    
IRCC = International Robotic Cystectomy Consortium; PSM = positive surgical margin; RCT = randomized controlled trial; UNC = 
University of North Carolina. 
 
  
Table 4 ± Predictors of positive surgical margins in robot-assisted radical cystectomy series 
 
Reference Institution 
IDEAL 
stage 
Cases  Study design 
Pathologic stage,% 
Overall PSM 
rate, % 
PSM rate, %  ? ?  ? ?  ? ?  ? ? 
Case volume                   
Guru et al, 2008 
[59] 
Roswell Park Cancer 
Institute 
2a 
 1Ȃ12 
Prospective 
33 66 17 
Ȃ Ȃ  13Ȃ24 58 42 25  25Ȃ36 50 50 0 
 37Ȃ47 46 54 9 
 48Ȃ58 64 36 0 
Hayn et al, 2011 
[64] 
Roswell Park Cancer 
Institute 
2a 
 1Ȃ50  
Prospective 51 49 
8 Ȃ Ȃ  51Ȃ100 12 
101Ȃ164 6 
Richards et al, 2011 
[38] 
Wake Forest 
University 
2b 
60 
Retrospective 
63 37 10 
Ȃ Ȃ  1Ȃ20 55 45 5 
 21Ȃ40 70 30 5 
 41Ȃ60 65 35 20 
Schumacher et al, 
2011 [39] 
Karolinska Institute 2b 
45 
Retrospective 
78 22 2 
0 10 
 1Ȃ15 87 13 0 
 16Ȃ30 67 33 7 
 31Ȃ45 80 20 0 
Azzouni et al, 2013 
[63] 
Roswell Park Cancer 
Institute 
2b 
100 
Retrospective 
35 65 4 
Ȃ Ȃ  1Ȃ25 36 64 4  26Ȃ50 40 60 4 
 51Ȃ75 44 56 4 
 76Ȃ100 20 80 4 
Previous RARP 
experience 
                  
Hayn et al, 2010 
[61] 
IRCC 2b 
482 
Retrospective 
64 36 7 Ȃ Ȃ  ? ? ?RARP: 83 68 32 4 
51Ȃ100 
previous RARP: 
76 24 5 
Table
173 
101Ȃ150 
previous RARP: 
168 
54 46 9.5 
>150 previous 
RARP: 48 
42 58 12.5 
        
Patient BMI                   
Butt et al, 2008 [65] 
Roswell Park Cancer 
Institute 
2a 
BMI <25: 14 
Retrospective 
64 36 0 
0 Ȃ BMI 25Ȃ29: 18 28 72 28  ? ? ?ǣ ? ? 42 58 6 
Poch et al, 2012 
[46] 
Roswell Park Cancer 
Institute 
2b 
56 
Retrospective 
55 45 
Ȃ Ȃ Ȃ BMI <25: 14 50 50 
BMI 25 to <30: 
21 
57 43  ? ? ?ǣ21 52 48 
Intracorporeal vs 
extracorporeal 
diversion 
                  
Kang et al, 2012 
[85] 
Korea University 
School of Medicine 
2a 
38 
extracorporeal 
diversion 
Retrospective 
76 24 2.5 Ȃ Ȃ 
4 
intracorporeal 
diversion 
100 0 0 
BMI = body mass index; IRCC = International Robotic Cystectomy Consortium; PSM = positive surgical margin; RARP = robot-
assisted radical prostatectomy. 
Table 5 ± Survival outcomes in robot-assisted radical cystectomy series 
 
Reference Institution 
IDEAL 
stage 
Cases, 
no. 
Study 
design 
Follow-
up, mo 
Neoadjuvant 
chemotherapy, 
% 
Adjuvant 
chemotherapy, 
% 
DFS 
estimates, %  
CSS 
estimates, % 
OS estimates, 
% 
1 yr 
3 
yr 
5 
yr 
1 yr 
3 
yr 
5 
yr 
1 yr 
3 
yr 
5 
yr 
Pruthi et al, 
2008 [15] 
UNC 2b 50 Retrospective 13.2 0 22 Ȃ Ȃ Ȃ 94 (13 
mo) 
Ȃ Ȃ 90 (13 
mo) 
Ȃ Ȃ 
Murphy et 
al, 2008 
[12] 

ǯ 
Hospital 
2a 23 Retrospective 17 29 Ȃ  Ȃ Ȃ Ȃ Ȃ Ȃ Ȃ Ȃ Ȃ 91 
(17 
mo) 
Josephson 
et al, 2010 
[24] 
City of Hope 
Cancer 
Center 
2b 58 Retrospective 12 22 Ȃ Ȃ 76 (2 
yr) 
Ȃ Ȃ 76 (2 
yr) 
Ȃ Ȃ 54 (2 
yr) 
Ȃ 
Kang et al, 
2010 [25] 
Multicenter 2b 104 Retrospective 12 Ȃ Ȃ 96 Ȃ Ȃ Ȃ Ȃ Ȃ Ȃ Ȃ Ȃ 
Kauffman 
et al, 2011 
[27] 
Cornell 2b 85 Retrospective 18 20 12 79 
73 
  88 
85 
(2 
yr) 
  83 
79 
  (2 
yr) 
(2 
yr) 
Martin et 
al, 2010 
[30] 
Mayo 
Arizona 
2b 59 
Multi-
institutional 
21 17 Ȃ 82 71 Ȃ Ȃ Ȃ Ȃ 82 72 Ȃ 
Tulane 
University 
Pruthi et al, 
2010 [31] 
UNC 2b 100 Retrospective 21.2 5 18 Ȃ Ȃ Ȃ 94 (21 
mo) 
Ȃ Ȃ 91 (21 
mo) 
Ȃ Ȃ 
Canda et al, 
2012 [33] 
Ankara 
Ataturk 
Training and 
Research 
Hospital 
2a 27 Not reported 6 Ȃ 4 85 (6 
mo) 
Ȃ Ȃ 89 (6 
mo) 
Ȃ Ȃ 72 (6 
mo) 
Ȃ Ȃ 
Mmeje et 
al, 2013 
[45] 
Mayo 
Arizona 
2b 50 
Multi-
institutional 
41.5 12 46 Ȃ 43 39 Ȃ Ȃ Ȃ Ȃ 55 45 
UNC 
Treiyer et 
al, 2012 
[49] 
Saarland 
University 
2b 91 Retrospective 15 0 Ȃ Ȃ Ȃ Ȃ 94 Ȃ Ȃ 93 Ȃ Ȃ (15 
mo) 
(15 
mo) 
Collins et 
al, 2013 
[52] 
Karolinska 
Institute 
2b 113 Prospective 25 31 Ȃ Ȃ Ȃ Ȃ Ȃ 81 67 Ȃ 80 66 
Khan et al, 
2013 [66] 

ǯƬ. 
Thomas 
Hospital 
1 14 Prospective 84 28 14 50 75 64 
Nepple et Washington 2b 36 Retrospective 12 6 Ȃ Ȃ 67 Ȃ Ȃ 75 Ȃ Ȃ 68 Ȃ 
Table
al, 2013 
[82] 
University (2 
yr) 
(2 
yr) 
(2 
yr) 
Snow-Lisy 
et al, 2014 
[67] 
Cleveland 
Clinic 
2b 17 Retrospective 67 Ȃ Ȃ Ȃ Ȃ Ȃ Ȃ Ȃ 69 Ȃ Ȃ 39 
Tyritzis et 
al, 2013 
[56] 
Karolinska 
Institute 
2b 70 Retrospective 30.3 24 Ȃ Ȃ 81 (2 
yr) 
Ȃ Ȃ 89 (2 
yr) 
Ȃ Ȃ 89 (2 
yr) 
Ȃ 
Xylinas et 
al, 2013 
[57] 
Cornell 2b 175 Retrospective 37   19 Ȃ 67 63 Ȃ 68 66 Ȃ Ȃ Ȃ 
Raza et al, 
in press 
[70] 
Roswell Park 
Cancer 
Institute 
2b 99 Retrospective 73.9 6 29 Ȃ Ȃ 53 Ȃ Ȃ 68 Ȃ Ȃ 42 
Yuh et al, 
2014 [58] 
City of Hope 
Cancer 
Center 
2b 162 Retrospective 52 23 Ȃ Ȃ 76 74 Ȃ 83 80 Ȃ 61 54 
CSS = cancer-specific survival; DFS = disease-free survival; OS = overall survival; UNC = University of North Carolina. 
Table 6 ± Urinary continence rates in robot-assisted radical cystectomy series 
 
 
Reference Institution 
IDEAL 
stage 
Cases
, no. 
Study 
design 
Nerve-
sparing 
surgery, 
% 
Intracorporeal 
diversion, % 
Follow-
up, mo 
Method of 
data 
collection 
Continence 
definition 
Continence rate, % 
 
  
3 
mo 
6 mo 12 mo 
Mottrie et 
al, 2007 [9] 
O.L.V.ȂClinic 2a 27 Retrospective 29 0 10.2 Ȃ Ȃ 86 Ȃ Ȃ 
Murphy et 
al, 2008 
[12] 

ǯ Hospital 2a 23 Retrospective 20 0 17 Ȃ Ȃ Ȃ Ȃ  100 D 
75 N 
 (17 mo) 
Palou 
Redorta et 
al, 2009 
[20] 
Barcelona 
Autonomous 
University 
2a 9 Retrospective 100 0 7 Ȃ Ȃ   100  D and N 
(7 mo) 
  
Canda et al, 
2012 [33] 
Ankara 
Ataturk 
Training and 
Research 
Hospital 
2a 27 Not reported 89 100 6 Ȃ 
D: 0Ȃ1 safety 
pads Ȃ 48 Ȃ 
N: dry with no 
protection 
11 
Jonsson et 
al, 2011 
[35] 
Karolinska 
Institute 
2b 36 Prospective 55 100 25 Ȃ 0Ȃ1 pads Ȃ Ȃ 83 D 
 66 N 
Manoharan 
et al, 2011 
[37] 
University of 
Miami 
2a 14 Retrospective Ȃ 0 Ȃ Ȃ Ȃ 93 D 
71 N 
Torrey et 
al, 2012 
[41] 
City of Hope 
Cancer Center 
2b 34 Retrospective 0 
0 (all  
12.1 
Physician 
charting 
Ȃ Ȃ Ȃ 97 
Indiana pouch) 
Goh et al, 
2012 [43] 
Keck School 
of Medicine, 
University of 
Southern 
California, Los 
Angeles 
2a 15 Prospective Ȃ 100 3 Ȃ Ȃ 75     
Tyritzis et 
al, 2013 
[56] 
Karolinska 
Institute 
2b 70 Retrospective 
58 BNS 
100 12 
Internally 
validated 
questionnaire 
0Ȃ1 pads Ȃ D: 77 men, D: 88 men, 
8 UNS 
40 
women 
 
67 
women 
Table
N:  
54 men, 
40 
women 
    N:  
76 men, 
76 
women 
 
BNS = bilateral nerve sparing; D = daytime; N = nocturnal; UNS = unilateral nerve sparing. 
Table 7 ± Erectile function in robot-assisted radical cystectomy series 
 
 
Reference Institution 
IDEAL 
stage 
Cases, 
no. 
Nerve-
sparing 
surgery, % 
Study 
design 
Follow-
up, mo 
Method of 
data 
collection 
Potency 
definition 
Potency rate 
at follow-up 
Mottrie et al, 
2007 [9] 
O.L.V.ȂClinic 2a 27 29 Retrospective 10.2 Ȃ Ȃ 86% 
Murphy et al, 
2008 [12] 

ǯ Hospital 2a 23 20 Retrospective 17 IIEF IIEF >21 with or 
without PDE5-I 
75% 
Palou Redorta 
et al, 2009 [20] 
Barcelona 
Autonomous 
University 
2a 9 100 Retrospective 7 Ȃ Ȃ 100% 
Akbulut et al, 
2011 [32] 
Ankara Ataturk 
Training and Research 
Hospital 
2a 12 
82 bilateral  
 Not reported 7.1 IIEF None provided 
A single patient 
with IIEF >18 9 unilateral 
Canda et al, 
2012 [33] 
Ankara Ataturk 
Training and Research 
Hospital 
2a 27 89 Not reported 6 IIEF None provided 
A single patient 
with IIEF >18 
Jonsson et al, 
2011 [35] 
Karolinska Institute 2b 36 55 Prospective 25 IIEF 
Adequate for 
penetration with or 
without PDE5-I 
41% at 12 mo 
75% of patients 
having nerve 
sparing 
Tyritzis et al, 
2013 [56] 
Karolinska Institute 2b 70 
58 bilateral 
Retrospective 12 IIEF 
Adequate for 
penetration with or 
without PDE5-I 
81% at 12 mo 
8 unilateral 
IIEF = International Index of Erectile Function; PDE5-I = phosphodiesterase type 5 inhibitor. 
Table
Table 8 ± Comparative studies evaluating lymph node yield after open, laparoscopic, and robot-assisted radical cystectomy 
 
Comparison 
Level of 
evidence 
Reference Cases, no. 
Study 
design 
Extension of 
LND 
Retrieved 
nodes, no.  
pN+, no. (%) 
Metastatic 
nodes, no., 
median  
ORC vs RARC 2               
    
Nix et al, 
2010 [74] 
21 RARC 
RCT Standard 
19 4 (19) Ȃ 
20 ORC  18 7 (35) 
    
Parekh et al, 
2013 [83] 
20 RARC  
RCT Standard 
17.2 ± 13 4 (20) Ȃ 
20 ORC  24.2 ± 16.4 4 (20) 
  3               
    
Pruthi et al, 
2008 [71] 
20 RARC  
Gender 
matched 
Standard 
19 2 (10) Ȃ 
24 ORC  Retrospective 16 5 (21)  
    
Wang et al, 
2008 [72] 
33 RARC  
Nonmatched Standard 
17 19 Ȃ 
21 ORC  20 34*  
    
Ng et al, 2010 
[73] 
83 RARC  
Nonmatched Standard 
17.9 ± 10.4 13 (16) Ȃ 
104 ORC  15.7 ± 13.2 24 (23)* 
    
Richards et al, 
2010 [75] 
35 RARC  
Nonmatched Extended 
16 10 (29)  Ȃ 
35 ORC  15 10 (29) 
    
Martin et al, 
2011 [76] 
19 RARC  
Nonmatched Ȃ 16 Ȃ Ȃ 
14 ORC  13 
    
Gondo et al, 
2012 [92] 
11 RARC 
Nonmatched Extended 
 
20.7 ± 8.2 
13.8 ± 6.6* 
9 Ȃ 
15 ORC 
 
13 
    
Khan et al, 
2012 [87] 
48 RARC 
Prospective Extended 
16 5 Ȃ 
52 ORC 11 15 
    
Richards et al, 
2012 [77] 
20 RARC  
Nonmatched Extended 
17 7 (35)  Ȃ 20 ORC (>75 
yr) 
15 3 (15)  
    
Styn et al, 
2012 [78] 
50 RARC  1:2 by age, sex, 
clinical stage, 
diversion 
Ȃ 14.3 ± 9.1 6 (12)  Ȃ 
100 ORC  15.2 ± 9.5 19 (19) 
    
Sung et al, 
2012 [79] 
35 RARC  
Nonmatched Standard 
19.1 ± 8.2 9 (26) Ȃ 
104 ORC  12.9 ± 9.0 * 27 (26) 
Table
    
Knox et al, 
2013 [86] 
58 RARC 
Nonmatched Extended 
21 1 Ȃ 
84 ORC 17 3 
    
Maes et al, 
2013 [80] 
14 RARC  
Nonmatched Extended 
11.9 1 (7) Ȃ 
14 ORC  9.5 5 (35) 
    
Musch et al, 
2014 [81] 
100 RARC  
Nonmatched Ȃ 27.5 ± 11.0  20 (20)  Ȃ 
42 ORC  19.6 ± 8.8* 9 (21) 
    
Nepple et al, 
2013 [82]  
36 RARC  
Nonmatched Standard 
17 8 (22)  Ȃ 
29 ORC  14 7 (24) 
                  
  4 
Abaza et al, 
2012 [88] 
35 RARC 
Nonmatched Extended 
37.5 ± 13.2 12 (34) 1.5 
120 ORC 36.9 ± 14.8  36 (30) 2 
LRC vs RARC                 
  3 
Khan et al, 
2012 [87] 
48 RARC 
Prospective Extended 
16 5 Ȃ 
58 LRC 10 10 
  4 
Abraham et 
al, 2007 [89] 
14 RARC 
Nonmatched 
10 extended 22.3 2 (10) 
  
20 LRC 16 extended 16.5 2 (12.5) 
LND = lymph node dissection; LRC = laparoscopic radical cystectomy: ORC = open radical cystectomy; RARC = robot-assisted 
radical cystectomy; RCT = randomized controlled trial. 
*
 Statistically significant. 
Table 9 ± Comparative studies evaluating positive surgical margins after open, laparoscopic, and robot-assisted radical 
cystectomy 
 
Comparison 
Level of 
evidence 
Reference Cases, no. 
Pathologic stage, %  Overall PSM, 
no. (%) 
PSM in pT2 cancer 
pT2 pT3 
ORC vs RARC 2b            
    
Nix et al, 
2010 [74] 
21 RARC  67 14 0 0 
20 ORC 40 25 0 0 
    
Parekh et al, 
2013 [83] 
20 RARC  50 50 1 (5) 0 
20 ORC  65 35 1 (5) 0 
  3            
    
Rhee et al, 
2006 [84] 
7 RARC  86 14 0 0 
23 ORC  43 57 0 0 
    
Galich et al, 
2006 [90] 
13 RARC 54 46 0 Ȃ 
24 ORC 37 63 3 (12) 
    
Pruthi et al, 
2007 [71] 
20 RARC  78 22 0 
0 
24 ORC  63 37 0 
    
Wang et al, 
2008 [72] 
33 RARC  72 28 2 (6) Ȃ 
21 ORC  43 57 3 (14) 
    
Ng et al, 2010 
[73] 
83 RARC  61 39 6 (7) 0 
104 ORC  58 42 9 (9) 0 
    
Richards et al, 
2010 [75] 
35 RARC  60 40 1 (3)  Ȃ 
35 ORC  57 43 3 (9)  
    
Martin et al, 
2011 [76] 
19 RARC  42 58 Ȃ Ȃ 
14 ORC  93 7 
    
Gondo et al, 
2012 [92] 
11 RARC 91 9 1 (9) Ȃ 
15 ORC 53 47 2 (13) 
    
Khan et al, 
2012 [87] 
48 RARC 75 25 0 Ȃ 
52 ORC 50 50 6 (10) 
    
Richards et al, 
2012 [77] 
20 RARC  60 40 1 (5)  Ȃ 20 ORC (>75 
yr) 
50 50 2 (10) 
    Styn et al, 50 RARC  60 40 1 (2)  Ȃ 
Table
2012 [78] 100 ORC  72 28 1 (1) 
    
Sung et al, 
2012 [79] 
35 RARC  43 57 Ȃ Ȃ 
104 ORC  38 62 
    
Kader et al, 
2013 [91] 
100 RARC 58 42 12 (12) Ȃ 
100 ORC 53 47 11 (11) 
    
Knox et al, 
2013 [86] 
58 RARC 66 34 4 (7) Ȃ 
84 ORC 43 57 7 (8) 
    
Maes et al, 
2013 [80] 
14 RARC  43 57 3 (21) Ȃ 
14 ORC  57 43 2 (14)  
    
Musch et al, 
2013 [81] 
100 RARC  61 39 2 (2) Ȃ 
42 ORC  57 43 1 (2)  
    
Nepple et al, 
2013 [82] 
36 RARC  53 47 2 (6)  0 
29 ORC  58 42 2 (7)  0 
  4 
Abaza et al, 
2012 [88] 
35 RARC 60 23 2 (6)  0 
120 ORC 45 42 8 (7) 0 
LRC vs RARC              
  3 
Khan et al, 
2012 [87] 
48 RARC 75 25 0 Ȃ 
58 LRC 57 43 2 (4) 
  4 
Abraham et 
al, 2007 [89] 
14 RARC Ȃ Ȃ 1 (7) 0 
20 LRC 0 Ȃ 
LRC = laparoscopic radical cystectomy; ORC = open radical cystectomy; PSM = positive surgical margin; RARC = robot-assisted 
radical cystectomy. 
Table 10 ± Comparative studies evaluating recurrence-free, cancer-specific, and overall survival estimates after open, 
laparoscopic, and robot-assisted radical cystectomy 
 
Comparison 
Level of 
evidence 
Reference Cases, no. 
Study 
design 
FollowȂup, 
mo 
Neoadjuvant 
chemotherapy, 
% 
DFS 
estimates, 
% 
CSS 
estimates, 
% 
OS 
estimates, 
% 
ORC vs RARC 3                 
    
Khan et al, 
2012 [87] 
48 RARC 
Prospective 38 Ȃ Ȃ 79 Ȃ 
52 ORC 69 
    
Nepple et al, 
2013 [82] 
36 RARC 
Nonmatched 12 
6 67 (2 yr) 75 (2 yr) 68 (2 yr) 
29 ORC 14 58 (2 yr) 63 (2 yr) 63 (2 yr) 
LRC vs RARC 3                 
    
Khan et al, 
2012 [87] 
48 RARC 
Prospective 38 Ȃ Ȃ 79 Ȃ 
58 LRC 93 
CSS = cancer-specific survival; DFS = disease-free survival; LRC = laparoscopic radical cystectomy; ORC = open radical 
cystectomy; OS = overall survival; RARC = robot-assisted radical cystectomy. 
 
Table
Figure 1 
 
 
105  papers finally included in the 
systematic review 
Data extracted from 98 papers included in 
the systematic review 
80 surgical series 25 comparative studies  
472 duplicate or triplicate publications 
excluded 
599 records screened in full text 
12 further papers included after updates of the literature 
search on April 17, 2014  
6 duplicate publications excluded 
1071 records identified in electronic search 
284 records identified in 
Medline search 
350  records identified in 
Scopus search 
437 records identified in 
Web of Science search 
65 surgical series reporting data on 
oncologic and functional outcomes 
22  comparative studies reporting data on 
oncologic and functional outcomes 
  
1 further paper published during the 
preparation of the manuscript draft  
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